JP2021506786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506786A5 JP2021506786A5 JP2020532551A JP2020532551A JP2021506786A5 JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5 JP 2020532551 A JP2020532551 A JP 2020532551A JP 2020532551 A JP2020532551 A JP 2020532551A JP 2021506786 A5 JP2021506786 A5 JP 2021506786A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cdr
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177190A JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | FcRn抗体およびその使用方法 |
| JP2025089576A JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | FcRn抗体およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Division JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | FcRn抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506786A JP2021506786A (ja) | 2021-02-22 |
| JP2021506786A5 true JP2021506786A5 (cg-RX-API-DMAC7.html) | 2021-05-13 |
| JP7420720B2 JP7420720B2 (ja) | 2024-01-23 |
Family
ID=65041911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | FcRn抗体およびその使用方法 |
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | FcRn抗体およびその使用方法 |
| JP2025089576A Active JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | FcRn抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | FcRn抗体およびその使用方法 |
| JP2025089576A Active JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | FcRn抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3723802A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7420720B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260008175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111712259A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018386193B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020011310A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3085751A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL275070A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202005021PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019118791A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| CN116234827B (zh) * | 2021-09-03 | 2026-07-14 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| MX2024007806A (es) * | 2022-01-17 | 2024-07-04 | argenx BV | Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos. |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| JP2026526949A (ja) | 2023-07-31 | 2026-08-10 | メディトックス インク. | 抗体及びそれを含む免疫疾患治療用薬学的組成物 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US8273351B2 (en) | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| BR112013030352B1 (pt) | 2011-06-02 | 2020-05-19 | Dyax Corp. | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| EP4241852A3 (en) | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | FcRn抗体およびその使用方法 |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EP3762027A4 (en) | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| CA3148826A1 (en) | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| CA3200972A1 (en) | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
-
2018
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 KR KR1020257042733A patent/KR20260008175A/ko active Pending
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 KR KR1020207019955A patent/KR102904658B1/ko active Active
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en not_active Abandoned
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP7904366B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016042A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526540A5 (cg-RX-API-DMAC7.html) | ||
| JP7442575B2 (ja) | Fcrn抗体及びその使用方法 | |
| US20240132603A1 (en) | Ccr8 antibody and application thereof | |
| JP7420720B2 (ja) | FcRn抗体およびその使用方法 | |
| ES2389781T3 (es) | Tratamiento de la inflamación articular crónica mediante un anticuerpo aglicosilado anti-CD3 | |
| US20220144946A1 (en) | Fcrn antibodies and methods of use thereof | |
| JP2025138661A (ja) | Fcrn抗体およびその使用の方法 | |
| US20140199299A1 (en) | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists | |
| BR112020012011A2 (pt) | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. | |
| JP6604204B2 (ja) | 新規抗ヒトbdca−2抗体 | |
| EA028678B1 (ru) | Нейтрализующие пролактиновый рецептор антитела и их терапевтическое применение | |
| KR20110043761A (ko) | 항-il-12/il-23 항체 | |
| EP2121763B1 (en) | Anti-idiotype monoclonal antibodies as mimotopes of the hiv gp120 antigen | |
| ES2274542T3 (es) | Anticuerpos frente al receptor del interferon alfa/beta. | |
| ES3001197T3 (es) | Agente de unión anti-adrenomedulina (ADM) para su uso en la terapia o prevención de síntomas de enfermedad | |
| CN105770889B (zh) | 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用 | |
| ES2273335T3 (es) | Uso de un anticuerpo no neutralizante especifico para la subunidad beta de la hormona luteinizante para aumentar la fertilidad. | |
| US12103969B2 (en) | Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof | |
| JP2021522795A (ja) | TGFβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 | |
| JP7654849B2 (ja) | 抗rankl抗体およびその使用 | |
| TWI790617B (zh) | 抗硬骨素抗體、其抗原結合片段及其醫藥用途 | |
| CN116854820B (zh) | Pd-1非阻断性清除抗体及其用途 | |
| AU2017225906A1 (en) | Methods of treating bone diseases, disorders and/or injuries and reagents therefor | |
| WO2020119707A1 (zh) | 抗il-17a抗体及其应用 |